Clopidogrel Current Events | Clopidogrel News
|
|
|
Sort By:
Page Views | Date |
Aspirin is most cost effective way to prevent heart disease
Aspirin and blood pressure lowering drugs can prevent heart disease at a fraction of the cost of cholesterol lowering drugs (statins) and clopidogrel (an anti-clotting drug), finds a study in this week's BMJ. view more (2003-11-26)
Combination Anti-Clotting Therapy Increases Risk Of Bleeding For People At High Risk of Recurrent Stroke
The combination of two anti-clotting agents, aspirin and clopidogrel- known to be beneficial for people with cardiovascular disease-should not be recommended treatment for patients who have cerebrovascular disease, conclude authors of a study in this week's issue of THE LANCET. Hans-Christoph Diener (University of Essen, Germany) and colleagues... view more... (2004-07-21)
High-dose anticlotting drug cuts heart attack, death risk in half
Pretreatment with double-dose anticlotting medication just before percutaneous coronary intervention (PCI) cuts the combined risk of heart attack and cardiac death by half. view more (2007-05-14)
Desensitization protocol overcomes allergy to clopidogrel
A careful desensitization protocol can help patients overcome allergic reactions to anti-clotting medication critical to preventing new blockages inside coronary stents. view more (2006-05-12)
Jefferson scientists find that plavix appears to be safe during and after heart bypass
Heart surgeons don't have to choose between taking a coronary-bypass patient off the popular anti-clotting drug clopidogrel (Plavix) after off-pump heart bypass surgery or having the patient bleed excessively in the days following surgery, according to a new study by researchers at Jefferson Medical College. view more (2007-03-28)
Genetic variation associated with poorer response, cardiovascular outcomes with use of clopidogrel
Patients with a certain genetic variation who received the antiplatelet drug clopidogrel had a decreased platelet response to treatment and among those who had percutaneous coronary intervention (procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries) had an increased risk of having a cardiovascular event... view more... (2009-08-26)
Study shows benefits of anti-clotting medications reduced by common heartburn drugs
The anti-clotting action of the medication clopidogrel (Plavix) can be compromised by common drugs for the treatment of heartburn and ulcers resulting in a roughly 50% increase in the combined risk of hospitalization for heart attack, stroke and other serious cardiovascular illnesses. view more (2009-05-07)
Long-term anti-clotting therapy sweetens stenting outcomes in diabetic patients
A study showing that diabetic patients who are treated with long-term anti-clotting therapy are less likely to have a heart attack or die more than a year after stenting has been named among the best research papers presented at the 30th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions (SCAI), May 9-12,... view more... (2007-05-18)
Cogent trial shows lack of adverse interaction between clopidogrel and stomach medicine
Results from a late breaking clinical trial called COGENT demonstrate that the combination of giving patients clopidogrel, a blood thinner commonly prescribed to patients with cardiovascular disease, and stomach medicines such as omeprazole, known as proton pump inhibitors (PPIs), did not lead to adverse events, as some prior studies had suggested. view more (2009-09-25)
Part of drug trial for patients with atrial fibrillation discontinued
Study treatments for the ACTIVE W trial of the ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) program have been discontinued due to a significant difference in efficacy, in favour of the standard oral anticoagulation (OAC) over antiplatelet therapy (clopidogrel plus aspirin). view more (2005-09-07)
Proton pump inhibitors increase risk of heart attacks for patients on common cardiac drug
Patients taking the common cardiac drug clopidogrel following a heart attack are at a significantly higher risk of a recurrence if they are also taking widely used acid-lowering medications called proton pump inhibitors, a new study published online in CMAJ has found (http://www.cmaj.ca/cgi/rapidpdf/cmaj.082001). view more (2009-01-29)
Post-stent maintenance therapies questioned
Patients admitted to the hospital with an acute coronary syndrome (ACS) are often treated with a catheter-based procedure known as percutaneous coronary intervention, or PCI. But doctors are unclear about the optimal antithrombotic therapy to prescribe after procedure to prevent clotting. view more (2006-03-15)
Study Finds Half of Patients Undergoing Cerebrovascular Stent Placement Respond Poorly to the Antiplatelet Drug Clopidogrel (Plavix)
A study by researchers at Rush University Medical Center, published in the February issue of the American Journal of Neuroradiology, finds that half of patients undergoing cerebrovascular stent placement did not respond well to clopidogrel. Clopidogrel (Plavix) and aspirin are medications routinely prescribed for 1-3 months following... view more... (2008-02-06)
Combination of ASA and clopidogrel reduces heart attack risk in patients with acute coronary syndrome
In order to better prevent blood clots, clopidogrel can be prescribed to patients with acute ischaemia of the heart muscle, in addition to acetylsalicylic acid (ASA). The Institute for Quality and Efficiency in Health Care (IQWiG) has now investigated whether the combination of clopidogrel and ASA actually has a higher benefit for patients than... view more... (2009-04-22)
Aspirin treatment failure warning
Treatment failures occur with any drug and aspirin is no exception. Evidence is growing that some people will not respond to the anti-coagulant action of aspirin and the drug will not protect against cardiovascular events despite its regular intake. view more (2005-08-10)
Triple antiplatelet therapy appears superior to dual antiplatelet therapy
Results of five research studies and a clinical registry first-report presentation scheduled for the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF), suggest that triple antiplatelet therapy for patients undergoing percutaneous coronary intervention (PCI)... view more... (2008-10-14)
University of Maryland researchers identify gene variant linked to effectiveness of plavix
Researchers at the University of Maryland School of Medicine have identified a common gene variant carried by as many as a third of the general population that is believed to play a major role in determining why people do not respond to a popular anti-clotting medication, Plavix. view more (2009-08-26)
Reducing Blockage Fails to Improve Access to the Bloodstream for Kidney Dialysis
Reducing early blockages in bloodstream access for kidney failure treatment does not increase the likelihood that the access will function adequately for long-term treatments, according to a study funded by the National Institutes of Health. Results were published May 14, 2008, in the Journal of the American Medical Association. view more (2008-05-23)
Bare-metal stents are better for some heart patients
While drug-eluting stents are effective in keeping open diseased heart arteries, they should not be used for patients who need to have non-cardiac surgery a short time after an interventional heart procedure. view more (2007-05-14)
More patients with drug-coated cardiac stents survive, avoid costly follow-up procedures
The more than ten million Americans who've received drug-eluting stents to open their blocked coronary arteries have a bright future, according to new research from the University of Pennsylvania School of Medicine. view more (2008-05-23)
|
|
|
|
Sort By:
Page Views | Date |
|
